Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Onconetix, Inc. (ONCO) on December 10, 2025, covering events occurring on December 5, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Cincinnati, Ohio. The report details executive compensation adjustments and the results of the 2025 Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Interim CEO Bonus: $45,000 approved for Karina Fedasz for 2025 service, payable in January 2026.
- Base Compensation Increase: $5,000 per month increase for Karina Fedasz, effective January 1, 2026.
Material Changes and Corporate Actions
The filing reports the following material corporate actions approved by the Board and stockholders:
- Board Elections: Thomas Meier was re-elected and Sarah Romano was elected as Class I directors for a three-year term expiring in 2028.
- Capital Structure Approvals: Stockholders approved the issuance of shares upon conversion of Series D and Series E Preferred Stock and exercise of related warrants (PIPE transactions) to comply with Nasdaq Listing Rule 5635.
- Series D PIPE: Up to 4,424,080 shares from Preferred Stock conversion and 4,362,827 shares from warrant exercise.
- Series E PIPE: Up to 2,025,223 shares from Preferred Stock conversion and 2,025,223 shares from warrant exercise.
- Auditor Ratification: MaloneBailey, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Voting Results and Management Commentary
All five proposals presented at the Annual Meeting were approved. The record date for the meeting was October 21, 2025, with 1,555,010 shares of Common Stock outstanding. Key voting statistics include:
- Director Elections: Thomas Meier received 323,739 votes for; Sarah Romano received 320,886 votes for.
- Series D & E PIPE Proposals: Both received approximately 316,344-316,346 votes for, with roughly 12,288-12,290 votes against.
- Auditor Ratification: Received 588,242 votes for and 63,447 votes against.
- Adjournment Proposal: Received 579,157 votes for and 78,873 votes against.
The filing contains no specific management commentary regarding future outlook, risks, or contingencies beyond the standard disclosures of the voting results and compensation approvals.
Investor Verification Checklist
- Verify the total dilution impact of the approved Series D and Series E PIPE conversions and warrant exercises.
- Confirm the closing dates and terms of the private placement transactions referenced (September 22, 2025, and October 1, 2025).
- Review the Company's cash position to ensure sufficiency for the upcoming $45,000 bonus payment and increased monthly executive compensation.
- Monitor the transition of leadership roles following the Interim CEO's compensation adjustment.